Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by Transperanceon Jan 05, 2023 9:29am
171 Views
Post# 35204515

RE:RE:RE:End Dec 2019 vs End Dec 2022

RE:RE:RE:End Dec 2019 vs End Dec 2022biorun,

1 You stated that "Linda Pullen said it was a solid agreement for Sirona."

This is not accurate. 

Linda Pullan stated “Allergan Aesthetics’ global presence in the aesthetic space and goal to further enhance aesthetic medicine combined with Sirona’s disruptive technology made this all possible”.

Whether the agreement is solid or not was not commented. 

2 You stated that "The CEO then said that this agreement will make Sirona profitable. Anyone that can read a financial statement can figure out what that means, at minimum. There is your financial forecast."

A CEO statement without figures is not a financial forecast. The basic problem with this company is that you cannot do any forcast and you cannot do a due diligence since no figures are provided.





<< Previous
Bullboard Posts
Next >>